Cargando…

Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study

BACKGROUND: Adherence to direct oral anticoagulants (DOACs) in patients with atrial fibrillation in every day practice may be less than in clinical trials. AIMS: To assess adherence to DOACs in atrial fibrillation patients in every day practice and identify predictors for non‐adherence. METHODS: Ind...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zielinski, Gilda D., van Rein, Nienke, Teichert, Martina, Klok, Frederikus A., Rosendaal, Frits R., van der Meer, Felix J. M., Huisman, Menno V., Cannegieter, Suzanne C., Lijfering, Willem M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360064/ https://www.ncbi.nlm.nih.gov/pubmed/33822401 http://dx.doi.org/10.1002/pds.5242

Ejemplares similares

Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study
por: Zielinski, Gilda Denise, et al.
Publicado: (2019)

Self‐reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

Inter‐ and intra‐individual concentrations of direct oral anticoagulants: The KIDOAC study
por: Toorop, Myrthe M. A., et al.
Publicado: (2021)

Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

Stability of vitamin K antagonist anticoagulation after COVID‐19 diagnosis
por: Camilleri, Eleonora, et al.
Publicado: (2021)

Time Trends in Patient Characteristics, Anticoagulation Treatment, and Prognosis of Incident Nonvalvular Atrial Fibrillation in the Netherlands
por: Chen, Qingui, et al.
Publicado: (2023)

Coagulation factors II, V, VII, IX, X and XI and mortality – a cohort study
por: Yap, Eng Soo, et al.
Publicado: (2023)

The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment
por: Kooiman, Judith, et al.
Publicado: (2015)

Efficacy and Safety of Vitamin K-Antagonists (VKA) for Atrial Fibrillation in Non-Dialysis Dependent Chronic Kidney Disease
por: Kooiman, Judith, et al.
Publicado: (2014)

Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review
por: van der Wall, Sake J., et al.
Publicado: (2018)

Risk prediction of recurrent venous thrombosis; where are we now and what can we add?
por: Timp, Jasmijn F., et al.
Publicado: (2019)

Higher Adherence to Treatment With Low-Molecular-Weight-Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer-Associated Venous Thromboembolism
por: van der Wall, Sake J., et al.
Publicado: (2018)

Quality of initial anticoagulant treatment and risk of CTEPH after acute pulmonary embolism
por: Boon, Gudula J. A. M., et al.
Publicado: (2020)

The joint effect of genetic risk factors and different types of combined oral contraceptives on venous thrombosis risk
por: Khialani, Deeksha, et al.
Publicado: (2020)

Correction: Quality of initial anticoagulant treatment and risk of CTEPH after acute pulmonary embolism
por: Boon, Gudula J. A. M., et al.
Publicado: (2020)

Risk of drug-related upper gastrointestinal bleeding in the total population of the Netherlands: a time-trend analysis
por: Bedene, Ajda, et al.
Publicado: (2022)

Lipid levels and risk of venous thrombosis: results from the MEGA-study
por: Morelli, Vânia M., et al.
Publicado: (2017)

Glucose levels and diabetes are not associated with the risk of venous thrombosis: results from the MEGA case‐control study
por: Li‐Gao, Ruifang, et al.
Publicado: (2018)

Predictors, time course, and outcomes of persistence patterns in oral anticoagulation for non-valvular atrial fibrillation: a Dutch Nationwide Cohort Study
por: Toorop, Myrthe M A, et al.
Publicado: (2021)

Association of apolipoproteins C-I, C-II, C-III and E with coagulation markers and venous thromboembolism risk
por: Orsi, Fernanda A, et al.
Publicado: (2019)

Causes and consequences of the opioid epidemic in the Netherlands: a population-based cohort study
por: Bedene, Ajda, et al.
Publicado: (2020)

Switching from vitamin K antagonists to direct oral anticoagulants in non‐valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence?
por: Toorop, Myrthe M. A., et al.
Publicado: (2021)

Procoagulant factors and future risk of arterial cardiovascular disease in patients with prior venous thrombosis: A cohort study
por: Yap, Eng Soo, et al.
Publicado: (2023)

Opioid Prescription Patterns and Risk Factors Associated With Opioid Use in the Netherlands
por: Bedene, Ajda, et al.
Publicado: (2019)

Comment on 'D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis'
por: Klok, Frederikus A., et al.
Publicado: (2019)

COVID‐19 associated coagulopathy and thromboembolic disease: Commentary on an interim expert guidance
por: Cannegieter, Suzanne C., et al.
Publicado: (2020)

Prevalence and Predictors of Nonadherence to Direct Oral Anticoagulant Treatment in Patients with Atrial Fibrillation
por: van der Horst, Sabine F. B., et al.
Publicado: (2023)

Pharmacological properties of betrixaban
por: Huisman, Menno V, et al.
Publicado: (2018)

First do no harm
por: Huisman, Menno V., et al.
Publicado: (2022)

Glucocorticoid use and risk of first and recurrent venous thromboembolism: self‐controlled case‐series and cohort study
por: Orsi, Fernanda A., et al.
Publicado: (2021)

Changes in incidence of hospitalization for cardiovascular diseases during the COVID-19 pandemic in The Netherlands in 2020
por: Kempers, Eva K., et al.
Publicado: (2023)

Comparison of Two Different Analgesic Prescription Strategies and Healthcare Systems: Slovenia vs. the Netherlands
por: Bedene, Ajda, et al.
Publicado: (2021)

Statin use and risk of recurrent venous thrombosis: results from the MEGA follow‐up study
por: Brækkan, Sigrid K., et al.
Publicado: (2017)

Treatment and prevention of cancer-associated thrombosis in the Netherlands: A national survey
por: Kaptein, Fleur H.J., et al.
Publicado: (2023)

Why crowding matters in the time of COVID-19 pandemic? - a lesson from the carnival effect on the 2017/2018 influenza epidemic in the Netherlands
por: Chen, Qingui, et al.
Publicado: (2020)

Factor V levels and risk of venous thrombosis: The MEGA case‐control study
por: Rietveld, Inge M., et al.
Publicado: (2018)

Risk and Risk Factors Associated With Recurrent Venous Thromboembolism Following Surgery in Patients With History of Venous Thromboembolism
por: Nemeth, Banne, et al.
Publicado: (2019)

Prediction of recurrent venous thrombosis in all patients with a first venous thrombotic event: The Leiden Thrombosis Recurrence Risk Prediction model (L-TRRiP)
por: Timp, Jasmijn F., et al.
Publicado: (2019)

Correction: Prediction of recurrent venous thrombosis in all patients with a first venous thrombotic event: The Leiden Thrombosis Recurrence Risk Prediction model (L-TRRiP)
por: Timp, Jasmijn F., et al.
Publicado: (2021)

Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism
por: Kooiman, Judith, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jlo3n0t51lkliehc9di3p11h20